VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment

Phase 1 Completed 33 enrolled Venatorx Pharmaceuticals, Inc. National Institutes of Health (NIH) · collab

Non-randomizedSingle-groupOpen-labelBasic science

Summary

This is a multi-center, open-label, PK and safety study of VNRX-5133 and VNRX-5022 when co-administered in male and female subjects with varying levels of renal impairment and healthy normal controls.

Timeline

Start: 2018-04-06
Primary completion: 2018-11-21
Completion: 2018-11-21

Publications

Dowell JA, Marbury TC, Smith WB, Henkel T. Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment. Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0025322. doi: 10.1128/aac.00253-22. Epub 2022 Aug 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cefepime	Small molecule	2 g	Intravenous
Subject	taniborbactam	Other / unclassified	0.5 g	Intravenous

Indications

No indication recorded.